Sub-nano Silicic Acid Modulation of ATPase Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases such as hypertension, diabetes, cardiovascular diseases, and cancer face challenges due to the toxicity and limited efficacy of existing inhibitors for ATPases and protein kinases, as well as the development of drug resistance in cancer cells, which necessitates the development of non-toxic and selective modulators for these targets.
Innovation Solution
The development of sub-nano silicic acid (SNSA) with a specific structure, characterized by a spheroidal form and high density of free Si-OH groups, which interacts with ATPases and proteins to modulate their activity, offering a novel approach for therapeutic intervention in diseases related to ATPase dysfunction and protein phosphorylation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cardiac steroids are used to inhibit Na,K-ATPase for treating cardiac insufficiency, then therapeutic effect is achieved, but toxicity increases significantly
Solution Approach 1:
The invention changes the chemical structure parameters of traditional cardiac steroids by replacing the steroid nucleus with a silicic acid core and modifying the substituent groups. This structural parameter change maintains the ability to bind to and inhibit Na,K-ATPase (therapeutic effect) while eliminating the toxicities associated with the steroid structure (cardiac arrhythmias, nephrotoxicity, hepatotoxicity).
Solution Approach 2:
The invention creates a composite molecular structure combining silicic acid core with organic substituent groups that mimic the binding characteristics of cardiac steroids. This composite approach allows the molecule to interact with the sodium pump receptor site while using a non-toxic inorganic-organic hybrid framework, thereby achieving therapeutic effects without the harmful side effects of pure organic cardiac steroids.
2Reliability
If vanadate compounds are used to inhibit ATPases for therapeutic purposes, then enzyme inhibition is achieved, but toxicity and tissue accumulation increase
Solution Approach 1:
The invention changes the chemical parameters by using silicic acid derivatives with specific molecular weights (1,000-100,000 Da) and controlled degrees of polymerization, rather than small inorganic vanadate ions. This parameter change allows for selective inhibition of target ATPases while the larger molecular size prevents rapid renal clearance and tissue accumulation, reducing toxicity.
Solution Approach 2:
The silicic acid compounds are designed to be metabolically unstable and rapidly eliminated from the body through normal physiological pathways, unlike vanadate compounds that accumulate in tissues. This 'short-living' design ensures that the inhibitory effect is transient and controllable, reducing the risk of chronic toxicity while maintaining therapeutic efficacy during the treatment period.
3Reliability
If monoclonal antibodies are used to block protein kinases in tumour therapy, then tumour-suppressive action is achieved, but immunogenicity increases leading to neutralization
Solution Approach 1:
The invention replaces large protein-based monoclonal antibodies with small molecule silicic acid derivatives that are not recognized as foreign by the immune system. These small molecules can freely cross cell membranes and inhibit protein kinases intracellularly without triggering antibody production, thereby maintaining tumour-suppressive effects without immunogenicity-related neutralization.
Solution Approach 2:
The invention substitutes the mechanical/physical approach of using large antibody proteins that bind extracellularly with a chemical approach using small silicic acid molecules that can penetrate cells and inhibit kinases at their site of action. This substitution of mechanism avoids the immunogenicity problem inherent in protein-based therapies while achieving the same functional outcome of kinase inhibition.
4Reliability
If existing ATPase inhibitors are used for treating hypertension and cardiovascular diseases, then therapeutic effect is achieved, but selectivity and efficacy are limited
Solution Approach 1:
The silicic acid derivatives are designed with specific local structural features (substituent groups at defined positions on the silicic acid core) that create high affinity and selectivity for particular ATPase isoforms involved in cardiovascular regulation. This local structural optimization allows preferential binding to target enzymes while minimizing off-target effects, enhancing both selectivity and therapeutic efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to low-molar mass condensed derivatives of silicic acid of sub-nano particle size characterised by particular structure and specific biological activities. Preparation methods and applications are presented for the here disclosed sub-nano silicic acid (SNSA) which interact with bio-molecules and modify significantly their structure and biological function. Preferred field of application of the inventive silicic acid derivatives is to modulate the structure and biological function of proteins particularly of those involved in reversible phosphorylation within biological signal transduction or membrane transport processes. Structure of the substances, methods for the preparation and stabilization, as well as pharmaceutical compositions comprising the substances and methods of application in the prevention, diagnosis and therapy of diseases are disclosed.